NASDAQ
1.53USD
-0.04 (-2.55%)
We have scored 4 news catalysts on Universe Pharmaceuticals Inc. (UPC) over the past 12 months. The biggest single-day move next to one of them came Jun 29, 2026, when UPC closed +311.5%: “Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday”. Coverage across the window leans negative (average ticker sentiment −0.12). Most of the impact sits in price momentum and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
966.6K
P/E
—
EPS
—
Beta
1.85
52W range
1.33-17.96
Day range
1.51–1.58
Open
1.51
Prev close
1.57
Volume
7.3K
Avg volume
1.5M
Dividend
0.00
IPO
2021-03-23
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Universe Pharmaceuticals Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for UPC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
